GSK plc announced that its RSV vaccine, Arexvy, received a positive opinion from the European Medicines Agency to expand its use to all adults aged 18 and older, with marketing authorization expected by February 2026. This is significant as, annually, about 158,000 adults in the EU are hospitalized due to RSV-related illnesses.